Cystic Fibrosis Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cystic Fibrosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Cystic Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Cystic Fibrosis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cystic Fibrosis Market.

The Cystic Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cystic Fibrosis Pipeline Report: https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Cystic Fibrosis treatment therapies with a considerable amount of success over the years.
• Cystic Fibrosis companies working in the treatment market are Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceuticals, 4D Molecular Therapeutics, Eloxx Pharmaceutical, Verona Pharma, Vertex Pharmaceuticals, and others, are developing therapies for the Cystic Fibrosis treatment
• Emerging Cystic Fibrosis therapies in the different phases of clinical trials are- SP-101, LUNAR CF, KB407, VX-522, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, and others are expected to have a significant impact on the Cystic Fibrosis market in the coming years.
• In September 2021, In order to assess the effectiveness and safety of VX-121 combination therapy in patients with cystic fibrosis (cf) who are heterozygous for f508del and a minimal function mutation (F/MF), Vertex Pharmaceuticals started a Phase III, randomised, double-blind, controlled research. This study's goal is to assess VX-121/tezacaftor/deutivacaftor's (VX-121/TEZ/D-IVA) effectiveness and safety in CF patients who are heterozygous for F508del and a minimal function mutation (F/MF patients).
• In May 2021, Vertex Pharmaceuticals Incorporated purchased the potential future milestones related to VX-561 (deutivacaftor) under the firms' 2017 asset purchase agreement for $32 million, according to an announcement from Concert Pharmaceuticals.

Cystic Fibrosis Overview
A mutation in the epithelial chloride channel protein CFTR leads to the genetic condition known as cystic fibrosis (CF), which is a recessive condition. The severity of CF, a hereditary illness that predominates, can range from moderate to life-threatening.

Get a Free Sample PDF Report to know more about Cystic Fibrosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Cystic Fibrosis Drugs Under Different Phases of Clinical Development Include:
• SP-101: Spirovant Sciences
• LUNAR CF: Arcturus Therapeutics
• KB407: Krystal Biotech
• VX-522: Vertex Pharmaceuticals
• Galicaftor/Navoc aftor/ABBV-576: AbbVie
• AP-PA02: Armata Pharmaceuticals
• 4D-710: 4D Molecular Therapeutics
• ELX-02: Eloxx Pharmaceutical
• Ensifentrine: Verona Pharma
• Deutivacaftor/tez acaftor/vanzacaft: Vertex Pharmaceuticals
• OligoG: Algi Pharma
• MRT5005: Translate Bio
• CB280: Calithera Biosciences
• KB407 : Krystal Biotech
• SPL84231: SpliSense

Cystic Fibrosis Route of Administration
Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Cystic Fibrosis Molecule Type
Cystic Fibrosis Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Cystic Fibrosis Pipeline Therapeutics Assessment
• Cystic Fibrosis Assessment by Product Type
• Cystic Fibrosis By Stage and Product Type
• Cystic Fibrosis Assessment by Route of Administration
• Cystic Fibrosis By Stage and Route of Administration
• Cystic Fibrosis Assessment by Molecule Type
• Cystic Fibrosis by Stage and Molecule Type

DelveInsight's Cystic Fibrosis Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Cystic Fibrosis product details are provided in the report. Download the Cystic Fibrosis pipeline report to learn more about the emerging Cystic Fibrosis therapies
https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cystic Fibrosis Pipeline Analysis:
The Cystic Fibrosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Cystic Fibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis Treatment.
• Cystic Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cystic Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cystic Fibrosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cystic Fibrosis drugs and therapies
https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cystic Fibrosis Pipeline Market Drivers
• Rising incidence of Cystic Fibrosis, advance research and development over the last few years have contributed to get a clearer picture of the disease, development of the healthcare industry are some of the important factors that are fueling the Cystic Fibrosis Market.

Cystic Fibrosis Pipeline Market Barriers
• However, no standard cure for cystic fibrosis, adverse effects associated with the drugs and other factors are creating obstacles in the Cystic Fibrosis Market growth.

Scope of Cystic Fibrosis Pipeline Drug Insight
• Coverage: Global
• Key Cystic Fibrosis Companies: Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceuticals, 4D Molecular Therapeutics, Eloxx Pharmaceutical, Verona Pharma, Vertex Pharmaceuticals, and others
• Key Cystic Fibrosis Therapies: SP-101, LUNAR CF, KB407, VX-522, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, and others
• Cystic Fibrosis Therapeutic Assessment: Cystic Fibrosis current marketed and Cystic Fibrosis emerging therapies
• Cystic Fibrosis Market Dynamics: Cystic Fibrosis market drivers and Cystic Fibrosis market barriers

Request for Sample PDF Report for Cystic Fibrosis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Cystic Fibrosis Report Introduction
2. Cystic Fibrosis Executive Summary
3. Cystic Fibrosis Overview
4. Cystic Fibrosis- Analytical Perspective In-depth Commercial Assessment
5. Cystic Fibrosis Pipeline Therapeutics
6. Cystic Fibrosis Late Stage Products (Phase II/III)
7. Cystic Fibrosis Mid Stage Products (Phase II)
8. Cystic Fibrosis Early Stage Products (Phase I)
9. Cystic Fibrosis Preclinical Stage Products
10. Cystic Fibrosis Therapeutics Assessment
11. Cystic Fibrosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cystic Fibrosis Key Companies
14. Cystic Fibrosis Key Products
15. Cystic Fibrosis Unmet Needs
16 . Cystic Fibrosis Market Drivers and Barriers
17. Cystic Fibrosis Future Perspectives and Conclusion
18. Cystic Fibrosis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Cystic Fibrosis Market
delveinsight.com/report-store/cystic-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Cystic Fibrosis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Cystic Fibrosis Epidemiology
https://www.delveinsight.com/report-store/cystic-fibrosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Cystic Fibrosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Patient Monitoring Devices Market https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028.

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028.

Resorbable Vascular Scaffolds Market https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Protein Supplements Market
https://www.delveinsight.com/report-store/protein-supplements-market
Protein Supplements Market By Source (Animal-Based [Whey, Casein, Fish, Eggs, Others], Plant-Based [Soy, Rice, Pea, Spirulina, Others]), By Product Type (Protein Powders, Protein Bars, Ready-To-Drink, And Others), By Application (Sports Nutrition And Functional Foods), By Distribution Channel (Supermarkets And Hypermarkets, E-Commerce, Direct-To-Consumer, Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2022-2027 owing to the growing consumer awareness of having a protein rich diet,

Proteomics Market
https://www.delveinsight.com/report-store/prostate-cancer-market-insight
Proteomics Market By Product & Services (Instrumentation Technology [Spectroscopy, Chromatography, Electrophoresis, Protein Microarrays, X-Ray Crystallography, And Other], Reagents & Consumables, And Software & Services), By Application (Clinical Diagnostics, Drug Discovery, And Others), By End-User (Hospitals, Clinical Laboratories, Pharmaceutical Companies, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2028.

Infrared Thermometer Market
https://www.delveinsight.com/report-store/infrared-thermometer-market
Infrared Thermometer Market By Product Type (Contact Thermometers And Non-Contact Thermometers), By End-User (Food And Beverage Industry, Electronic Industry, Healthcare Industry, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2028 owing to the growing need for robust temperature measuring devices in critical industries and rise in the number of infectious diseases across the globe.

Hemoglobinopathies Market
https://www.delveinsight.com/report-store/sport-nutrition-market
Hemoglobinopathies Market By Indication (Thalassemia, Sickle Cell Anaemia, And Others), By Treatment (Stem Cell Therapy, Blood Transfusion, Iron Chelation Therapy, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2027 owing to the increasing prevalence of various hemoglobin disorders and the increasing research & developmental activities concerning to the hemoglobinopathies across the globe

Sport Nutrition Market
https://www.delveinsight.com/report-store/sport-nutrition-market
The Sports Nutrition Market By Product Type (Sports Drinks And Sports Supplements), By Distribution Channels (Hypermarkets & Supermarkets, E-Commerce, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing inclination toward following healthy and active lifestyle and growing importance of sports nutrition among athletes and sportspersons.

Endodontic Devices Market
https://www.delveinsight.com/report-store/endodontic-devices-market
Endodontic Devices Market By Product Type (Instruments [Apex Locators, Endodontic Motors, Endodontic Scalers, Endodontic Lasers, Handpieces, Machine-Assisted Obturation Systems, And Others], Consumables [Obturation, Access Cavity Preparation, Shaping And Cleaning]), By End-User (Dental Hospitals, Dental Clinics, And Others), and by geography is estimated to register growth at a remarkable CAGR during the forecast period from 2023-2028 owing to the rising patient pool associated with dental disorders, poor oral health, leading to increased number of root canal treatments, the increasing population opting for dental aesthetics, among others across the globe.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.